Disclosures: MR Looney reported" other" from Neutrolis outside the submitted work. RE Schwartz is a Sponsored Advisory Board Member for Miromatrix Inc. JD Spicer reported personal fees from Bristol Myers Squibb, personal fees from Astra Zeneca, personal fees from Merck, personal fees from Trans-Hit Bio, and non-financial support from Astra Zeneca outside the submitted work. CC Yost reports a grant from PEEL Therapeutics, Inc. during the conduct of the study; in addition, CC Yost authors a US patent (patent no. 10,232,023 B2) held by the University of Utah for the use of NET-inhibitory peptides for" treatment of and prophylaxis against inflammatory disorders." PEEL Therapeutics, Inc. has exclusive licensing rights. M. Egeblad reported" other" from Santhera during the conduct of the study; and consulted for CytomX in 2019. No other disclosures were reported.